Inflammatory Disease News and Research RSS Feed - Inflammatory Disease News and Research

TUM scientists identify four new risk genes altered in MS patients

TUM scientists identify four new risk genes altered in MS patients

Scientists of the Technical University of Munich and the Max Planck Institute of Psychiatry have identified four new risk genes that are altered in German patients with multiple sclerosis (MS). [More]
PET imaging can help identify autoimmune inflammation in MS

PET imaging can help identify autoimmune inflammation in MS

The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular imaging is bringing researchers closer to identifying them, while providing a means of evaluating next-generation therapies for MS, say researchers introducing a study at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging. [More]
New stem cell treatment may halt clinical relapses, development of new brain lesions in patients MS

New stem cell treatment may halt clinical relapses, development of new brain lesions in patients MS

A new use of chemotherapy followed by autologous haematopoietic stem cell transplantation (aHSCT) has fully halted clinical relapses and development of new brain lesions in 23 of 24 patients with multiple sclerosis (MS) for a prolonged period without the need for ongoing medication, according to a new phase 2 clinical trial, published in The Lancet. [More]
Women with SLE may have increased cervical cancer risk

Women with SLE may have increased cervical cancer risk

The results of a study presented today at the European League Against Rheumatism Annual Congress found a doubled risk of pre-malignant cervical changes, and potentially also an increased risk of cervical cancer, among women with Systemic Lupus Erythematosus (SLE) compared to the general female population. [More]
New drug ixekizumab helps clear severe psoriasis symptoms

New drug ixekizumab helps clear severe psoriasis symptoms

About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine. [More]
Joint research reveals key mechanisms of persistent latent infection of HTLV-1

Joint research reveals key mechanisms of persistent latent infection of HTLV-1

Joint research between scientists from Kumamoto University, Japan and Imperial College London, UK has revealed the mechanisms of persistent latent infection of the human T-cell leukemia virus type 1 (HTLV-1). [More]
Gonorrhoea infections increase across Europe

Gonorrhoea infections increase across Europe

Since 2008, the overall rate of reported gonorrhoea infections has more than doubled across Europe, going up from 8 per 100 000 population to 20 cases per 100 000 persons in 2014. [More]
Sixty-ninth World Health Assembly comes to end after approving many new resolutions

Sixty-ninth World Health Assembly comes to end after approving many new resolutions

The Sixty-ninth World Health Assembly closed today after approving new resolutions on WHO's Framework for Engagement with Non-State Actors; the Sustainable Development Goals; the International Health Regulations; tobacco control; road traffic deaths and injuries; nutrition; HIV, hepatitis and STIs; mycetoma; research and development; access to medicines and integrated health services. [More]
ART alone not sufficient to reduce arterial inflammation among HIV-infected patients, study finds

ART alone not sufficient to reduce arterial inflammation among HIV-infected patients, study finds

Initiating antiretroviral therapy (ART) soon after diagnosis of an HIV infection did not prevent the progression of significant arterial inflammation in a small group of previously untreated patients. [More]
DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab. [More]
Non-invasive test to diagnose EoE could replace need for repeated endoscopy

Non-invasive test to diagnose EoE could replace need for repeated endoscopy

A non-invasive test to diagnose and monitor an inflammatory disease that injures the esophagus - called eosinophilic esophagitis or EoE - would replace the need for repeated endoscopy for a growing number of children and adults with this relatively new condition. [More]
Innovative ultrasound method can help determine risk of strokes, heart attacks

Innovative ultrasound method can help determine risk of strokes, heart attacks

Researchers at Lund University in Sweden have discovered a new and more accurate way to distinguish between harmful and harmless plaque in the blood vessels by using ultrasound. This can help healthcare providers determine the risk of strokes and heart attacks - which means avoiding unnecessary surgery for many patients. [More]
Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD). [More]
Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. [More]
Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis receives FDA Breakthrough Therapy designation for PKC412 (midostaurin)

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy designation to PKC412 (midostaurin). PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. [More]
New research identifies key enzyme linked to age-related increases in cancer and inflammation

New research identifies key enzyme linked to age-related increases in cancer and inflammation

For the first time, researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
BioLineRx's BL-7010 confirmed as Class IIb medical device in European Union

BioLineRx's BL-7010 confirmed as Class IIb medical device in European Union

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received confirmation from the European Notified Body regarding the classification of BL-7010, a novel polymer for the treatment of celiac disease, as a Class IIb medical device in the European Union. [More]
Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). [More]
NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine. [More]
Pelvic pain linked to poor mental health outcomes among women with endometriosis

Pelvic pain linked to poor mental health outcomes among women with endometriosis

A new study published in the Journal of Psychosomatic Obstetrics & Gynecology has found that women who suffer from pelvic pain caused by endometriosis may need psychological intervention in order to help improve their mental health and quality of life. [More]
Advertisement
Advertisement